In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MD Start – Can Medtech Incubators Work In Europe?

Executive Summary

Europe has historically been rich in physicians with innovative ideas but has lagged in turning those ideas into novel devices. MD Start, a new incubator, backed by a group of leading device companies and VC firms, hopes to turn those ideas into viable companies.

You may also be interested in...



Medtech Strategic/Start-Up Partnerships: Structuring For Success

According to a panel of strategic investors speaking at a recent IN3 meeting, structured deals that can help manage risk for medtech start-ups seeking funding and strategics looking for growth opportunities are on the rise.

Overcoming The Bias Against Medtech Entrepreneurship In Europe: An Interview With Martin Rothman

Why are European physicians so far ahead of the curve when it comes to innovative clinical practice and so far behind when it comes to creating companies? Interventional cardiologist and serial entrepreneur Martin Rothman offers some answers.

Medtech Investing In Europe: Nowhere To Go But Up

Even as the rest of the global economy seems somewhat on a path to recovery, medtech-focused VCs, in the US at least, are experiencing a time of significant uncertainty and attrition: fewer dollars available for new investments, a trend away from early-stage deals, and fewer and smaller venture firms overseeing smaller new funds. For European medtech investors, there has been little of the gloom and uncertainty that the US venture capital community has experienced over the past several years, if only because there was no pre-bust bubble from which to fall.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel